Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.
You may also be interested in...
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.
Provenge Coverage With Data Collection Suggested By MEDCAC Members
The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.